US89680M1018
© BusinessWire
04.12.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring J...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
News Preview
TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the TriNav® XP Infusion System, the latest advancement in the company’s portfolio of pressure-enabled drug delivery systems designed to improve...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operatio...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
11.11.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will partici...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
10.11.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuri...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela,...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy, announced today that it will host a conference call and webcast on Tuesday August 12, 2025 at 4:30 PM eastern time t...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, announced the completion of its previously disclosed exchange offer and consent solicitation for its Preferred Stock.
The offer expired one minute after 11:59 p.m. EDT on July 23, 2025. Under the terms of the offer, TriSalus provi...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy (“TriSalus” or the “Company”), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
News Preview
TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, is excited to announce the launch of the TriNav® FLX Infusion System, the latest additi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.05.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 20...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended March 31, 2025, and provides an operational...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agon...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
News Preview
TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
News Preview
TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has establi...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
News Preview
TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Key Appointments to Board of Directors
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its B...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously annou...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
News Preview
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call.
Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
Full financial results for the year ended December 31, 2024 are in the process of being final...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
TLSI
LISTED
NASDAQ
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
News Preview
TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
TLSI
LISTED
NASDAQ
TriSalus Announces Leadership Changes
News Preview
TriSalus Life Sciences, Inc., (Nasdaq: TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team.
James (Jim) Young, who previously...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
TLSI
LISTED
NASDAQ
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
News Preview
TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2024, and provided a business update.
“We enter the final quarter of 2024 w...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
TLSI
LISTED
NASDAQ
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
News Preview
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC (“Geo-Med”), a certified S...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
News Preview
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeu...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
News Preview
TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
News Preview
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will particip...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
News Preview
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB).
Dr. Sale...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
TLSI
LISTED
NASDAQ
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
News Preview
TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, “Intra-arterial Pressure-Enabled Drug D...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2024
TLSI
LISTED
NASDAQ
TriSalus Reports Q2 2024 Financial Results and Business Update
News Preview
TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the second quarter ended June 30, 2024, and provided a business update.
Mary Szela, President and Chief Executive...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
